- Sio has 3 clinical-stage gene therapies in neurodegeneration with over $80M in cash to bring this pipeline to several milestones.
- The company's lead program in GM1 gangliosidosis is expecting a 12-month data update by the end of the year to see if the program maintains its current positive results.
- The investment thesis is premised on Sio's promising clinical pipeline and business model along with a relative undervaluation when compared to other gene therapy companies with similar pipelines.
For further details see:
Sio Gene Therapies: Gene Therapies For Neurodegeneration